Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1984 2
1985 1
1988 1
1989 1
1993 2
1994 2
1995 1
1996 2
1998 1
1999 2
2000 2
2001 1
2002 2
2003 2
2004 4
2006 1
2008 2
2009 2
2010 3
2011 2
2012 1
2013 1
2014 2
2015 5
2016 4
2017 2
2018 6
2019 7
2020 3
2021 1
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Breast Adenocarcinoma"
Page 1
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Chowdhury S, Kennedy JJ, Ivey RG, Murillo OD, Hosseini N, Song X, Petralia F, Calinawan A, Savage SR, Berry AB, Reva B, Ozbek U, Krek A, Ma W, da Veiga Leprevost F, Ji J, Yoo S, Lin C, Voytovich UJ, Huang Y, Lee SH, Bergan L, Lorentzen TD, Mesri M, Rodriguez H, Hoofnagle AN, Herbert ZT, Nesvizhskii AI, Zhang B, Whiteaker JR, Fenyo D, McKerrow W, Wang J, Schürer SC, Stathias V, Chen XS, Barcellos-Hoff MH, Starr TK, Winterhoff BJ, Nelson AC, Mok SC, Kaufmann SH, Drescher C, Cieslik M, Wang P, Birrer MJ, Paulovich AG. Chowdhury S, et al. Cell. 2023 Aug 3;186(16):3476-3498.e35. doi: 10.1016/j.cell.2023.07.004. Cell. 2023. PMID: 37541199 Free PMC article.
We identified a 64-protein signature that predicts with high specificity a subset of HGSOCs refractory to initial platinum-based therapy and is validated in two independent patient cohorts. ...These clusters may represent different mechanisms of refractoriness …
We identified a 64-protein signature that predicts with high specificity a subset of HGSOCs refractory to initial platinum-bas …
Current status and future perspectives in HER2 positive advanced gastric cancer.
Roviello G, Catalano M, Iannone LF, Marano L, Brugia M, Rossi G, Aprile G, Antonuzzo L. Roviello G, et al. Clin Transl Oncol. 2022 Jun;24(6):981-996. doi: 10.1007/s12094-021-02760-0. Epub 2022 Jan 29. Clin Transl Oncol. 2022. PMID: 35091998 Review.
Gastric cancer is one of the most common malignancy worldwide with a prognosis less than 1 year in unresectable or metastatic disease. HER2 expression is the main biomarker to lead the addition of trastuzumab to first line systemic chemotherapy improving the overall surviv …
Gastric cancer is one of the most common malignancy worldwide with a prognosis less than 1 year in unresectable or metastatic disease …
Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease.
Hirai I, Tanese K, Nakamura Y, Ishii M, Kawakami Y, Funakoshi T. Hirai I, et al. Oncologist. 2019 Jun;24(6):e394-e396. doi: 10.1634/theoncologist.2018-0856. Epub 2019 Mar 7. Oncologist. 2019. PMID: 30846514 Free PMC article.
Extramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma that clinicopathologically resembles breast cancer. The prognosis of metastatic EMPD is poor. ...When treating breast cancer, anthracycline is regarded as the key cytotoxic agent, a …
Extramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma that clinicopathologically resembles breast cancer. The …
Canonical Kaiso target genes define a functional signature that associates with breast cancer survival and the invasive lobular carcinoma histological type.
Sijnesael T, Richard F, Rätze MA, Koorman T, Bassey-Archibong B, Rohof C, Daniel J, Desmedt C, Derksen PW. Sijnesael T, et al. J Pathol. 2023 Dec;261(4):477-489. doi: 10.1002/path.6205. Epub 2023 Sep 22. J Pathol. 2023. PMID: 37737015
Most ILC cases express estrogen receptors, but options are limited in relapsed endocrine-refractory disease as ILC tends to be less responsive to standard chemotherapy. ...Converting the ART genes into human orthologs and adding published Kaiso target genes resulted in the …
Most ILC cases express estrogen receptors, but options are limited in relapsed endocrine-refractory disease as ILC tends to be less r …
Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAFV600E-associated thyroid carcinoma.
Zhang P, Guan L, Sun W, Zhang Y, Du Y, Yuan S, Cao X, Yu Z, Jia Q, Zheng X, Meng Z, Li X, Zhao L. Zhang P, et al. Clin Transl Med. 2024 May;14(5):e1694. doi: 10.1002/ctm2.1694. Clin Transl Med. 2024. PMID: 38797942 Free PMC article.
BRAF(V600E)-mutated papillary thyroid cancer (PTC) also displays greatly reduced expression of thyroid differentiation markers, thus tendency to radioactive iodine (RAI) refractory and poor prognosis. Therefore, understanding the molecular mechanisms and main oncoge …
BRAF(V600E)-mutated papillary thyroid cancer (PTC) also displays greatly reduced expression of thyroid differentiation markers, thus tendenc …
Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
Rusinek D, Chmielik E, Krajewska J, Jarzab M, Oczko-Wojciechowska M, Czarniecka A, Jarzab B. Rusinek D, et al. Int J Mol Sci. 2017 Aug 22;18(8):1817. doi: 10.3390/ijms18081817. Int J Mol Sci. 2017. PMID: 28829399 Free PMC article. Review.
TCs represent a distinct molecular background and clinical outcome. Although in most cases TCs are characterized by a good prognosis, there are some aggressive forms, which do not respond to standard treatment. ...We discussed the controversies regarding the extent of thyr …
TCs represent a distinct molecular background and clinical outcome. Although in most cases TCs are characterized by a good prognosis, …
Benefits and risks of off-label olanzapine use for symptom management in cancer patients-a case report.
Dev R, Fortuno ES 3rd, Amaram-Davila JS, Haider A, Bruera E. Dev R, et al. Ann Palliat Med. 2023 May;12(3):600-606. doi: 10.21037/apm-22-1167. Epub 2023 Mar 14. Ann Palliat Med. 2023. PMID: 37038067 Free article.
Her nausea was refractory to multiple anti-emetics. Low dose olanzapine (2.5 mg) prevented nausea and allowed her to tolerate treatment. ...He also had symptoms of depression, poor appetite, and sleep problems. He was prescribed short course of dexamethasone 4 mg by …
Her nausea was refractory to multiple anti-emetics. Low dose olanzapine (2.5 mg) prevented nausea and allowed her to tolerate treatme …
Integrated analysis of single-cell and bulk RNA sequencing data reveals a myeloid cell-related regulon predicting neoadjuvant immunotherapy response across cancers.
Liu H, Sima X, Xiao B, Gulizeba H, Zhao S, Zhou T, Huang Y. Liu H, et al. J Transl Med. 2024 May 21;22(1):486. doi: 10.1186/s12967-024-05123-9. J Transl Med. 2024. PMID: 38773508 Free PMC article.
However, the majority of patients exhibit resistance or become refractory to immunotherapy, and the underlying mechanisms remain to be explored. ...A regulon predicting ICI response was identified and validated using large-scale pan-cancer data, including a colorect …
However, the majority of patients exhibit resistance or become refractory to immunotherapy, and the underlying mechanisms remain to b …
Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent.
Sinkule JA. Sinkule JA. Pharmacotherapy. 1984 Mar-Apr;4(2):61-73. doi: 10.1002/j.1875-9114.1984.tb03318.x. Pharmacotherapy. 1984. PMID: 6326063 Review.
Etoposide's dose-limiting toxicity is myelosuppression (leukopenia), which is quite predictable; alopecia and Gl toxicity (nausea, vomiting, stomatitis) occur in about 20-30% of patients given recommended dosages. ...Its contribution in front-line combination chemotherapeu …
Etoposide's dose-limiting toxicity is myelosuppression (leukopenia), which is quite predictable; alopecia and Gl toxicity (nausea, vo …
Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.
Martin-Castillo B, Lopez-Bonet E, Buxó M, Dorca J, Tuca-Rodríguez F, Ruano MA, Colomer R, Menendez JA. Martin-Castillo B, et al. Oncotarget. 2015 Mar 30;6(9):7104-22. doi: 10.18632/oncotarget.3106. Oncotarget. 2015. PMID: 25742793 Free PMC article.
There is an urgent need to refine the prognostic taxonomy of HER2+ breast carcinomas and develop easy-to-use, clinic-based prediction algorithms to distinguish between good- and poor- responders to trastuzumab-based therapy. Building on earlier studies sugges …
There is an urgent need to refine the prognostic taxonomy of HER2+ breast carcinomas and develop easy-to-use, clinic-based …
66 results